Table 1.
Demographic and clinical characteristics of study patients with vitiligo (n = 294)
| Variable n (%), median (min-max) |
The study sample (n = 294) |
|---|---|
| Age, years | 35 (3–86) |
| < 18 | 35 (11.9) |
| 18–39 | 153 (52.0) |
| 40–59 | 88 (29.9) |
| 60–79 | 17 (5.8) |
| ≥ 80 | 1 (0.3) |
| Sex | |
| Male | 133 (45.2) |
| Female | 161 (54.8) |
| Disease duration | 9 (0.10–54) |
| Age at vitiligo onset | 24 (1–84) |
| Course of the disease | |
| Stationary | 67 (22.8) |
| Regressive | 21 (7.1) |
| Progressive | 206 (70.1) |
|
Affected BSA, % 1–25 |
134 (45.6) |
| 26–50 | 131 (44.6) |
| 51–75 | 16 (5.4) |
| 76–100 | 13 (4.4) |
| Distribution | |
| Face or body | 268 (91.2) |
| Face and body | 26 (8.8) |
| Laterality | |
| Unilateral/midline | 241 (82.0) |
| Bilateral | 53 (18.0) |
| Family history of vitiligo | 62 (21.1) |
| Family history of AIIDs | 74 (25.2) |
| VIDA | |
| + 4 | 32 (10.9) |
| + 3 | 57 (19.4) |
| + 2 | 77 (26.2) |
| + 1 | 35 (11.9) |
| 0 | 32 (10.9) |
| -1 | 61 (20.7 |
| Treatment | |
| No | 141 (48) |
| Local | 131 (44.6) |
| Systemic | 12 (4.1) |
| Both local and systemic | 10 (3.4) |
AIIDs: autoimmune and autoinflammatory diseases, BSA: body surface area, VIDA: Vitiligo Disease Activity Score